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REVIEWPredicting bacteraemia in validated models—a systematic reviewN. Eliakim-Raz1,3, D. W. Bates4,5 and L. Leibovici2,3
1) Unit of Infectious Diseases Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 2) Department of Medicine E, Rabin Medical Center, Beilinson Hospital,
Petah-Tikva, 3) Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel, 4) Department of Medicine, Brigham and Women’s Hospital, Harvard Medical
School and 5) Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USAAbstractBacteraemia is associated with high mortality. Although many models for predicting bacteraemia have been developed, not all have been
validated, and even when they were, the validation processes varied. We identiﬁed validated models that have been developed; asked
whether they were successful in deﬁning groups with a very low or high prevalence of bacteraemia; and whether they were used in
clinical practice. Electronic databases were searched to identify studies that underwent validation on prediction of bacteraemia in
adults. We included only studies that were able to deﬁne groups with low or high probabilities for bacteraemia (arbitrarily deﬁned as
below 3% or above 30%). Fifteen publications fulﬁlled inclusion criteria, including 59 276 patients. Eleven were prospective and four
retrospective. Study populations and the parameters included in the different models were heterogeneous. Ten studies underwent
internal validation; the model performed well in all of them. Twelve performed external validation. Of the latter, seven models were
validated in a different hospital, using a new independent database. In ﬁve of these, the model performed well. After contacting
authors, we found that none of the models was implemented in clinical practice. We conclude that heterogeneous studies have
been conducted in different deﬁned groups of patients with limited external validation. Signiﬁcant savings to the system and the
individual patient can be gained by refraining from performing blood cultures in groups of patients in which the probability of true
bacteraemia is very low, while the probability of contamination is constant. Clinical trials of existing or new models should be done
to examine whether models are helpful and safe in clinical use, preferably multicentre in order to secure utility and safety in diverse
clinical settings.
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E-mail: noaeliakim@gmail.comIntroductionAmong patients with infection, bacteraemia portends a poor
prognosis, and clinicians’ ability to predict it is low [1,2]. Bac-
terial bloodstream infections are associated with mortality of
14% to 37% [3–6]. Knowledge (or high suspicion) that a patient
has a bloodstream infection can guide treatment—aggressively
(or not) treating the patient, transferring the patient to anClinical Microbiology and Infection © 2015 European Society of Cintensive care unit, empirically initiating appropriate antibiotic
treatment and thinking of differential diagnosis.
Poses and Anthony [7], in a prospective cohort study,
assessed inappropriate physicians’ judgements of the probability
of bacteraemia. They found that physicians signiﬁcantly over-
estimated the likelihood of bacteraemia for most of their pa-
tients. Their receiver operating characteristic (ROC) curve for
this diagnosis showed only moderate discriminating ability
(area = 0.687, SE = 0.073). Generally only about 5% to 10% of
blood cultures are positive, and of those that are positive, 30%
to 50% represent contaminants—organisms inoculated from
the skin into culture bottles at the time of sample collection
[8–11]. The costs of performing and handling negative and
false-positive blood culture results are signiﬁcant. False-positiveClin Microbiol Infect 2015; 21: 295–301
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unneeded antibiotic therapy. In one analysis, patients with
falsely positive blood cultures were compared with those with
truly negative blood cultures, and false-positive ﬁndings were
associated with a 50% increase in total charges and a 64% in-
crease in median length of hospitalization stay, along with higher
pharmacy charges and laboratory charges [12]. Deﬁning of a
group of patients with a very low probability of bacteraemia, in
which blood cultures are not necessary or not cost-effective,
has the potential to reduce costs and prevent unnecessary
antibiotic treatment. In addition, selection of a group with a high
likelihood for bacteraemia caused by speciﬁc pathogens could
assist physicians in choosing treatment or determining whether
to perform new, costly tests such as PCR testing for bacterial
and fungal DNA [13].
This is the logic for developing tools that can predict bac-
teraemia accurately in patients suspected of harbouring a
moderate to severe bacterial infection. To be useful, such a tool
should fulﬁl a few conditions. It should be able to deﬁne a group
with a very low prevalence of bacteraemia, and this group
should be of a useful size. We can be further reassured if the
few truly positive blood cultures included in this group were
expected and would have been covered by empirical antibiotic
treatment so that the results of the positive blood culture
would not have changed management. Deﬁnition of a group
with a high prevalence of bacteraemia might also be useful for
triaging patients for culture-free, expensive techniques of
looking for bacteria or their products in the blood. The tool
should use data that are readily available at the time of decision
making, within the time frame of the decision whether or not to
obtain blood samples for culture. It should be validated exter-
nally to assure its users that it performs well in multiple settings.
Many models for predicting bacteraemia have been devel-
oped. Some have been developed in speciﬁc populations of
adult patients (e.g. elderly, hematology–oncology populations,
neutropenic patients) or for speciﬁc settings (emergency room
(ED), community or hospitalized patients). Models have also
been developed for speciﬁc sources of infection (e.g. urinary
tract, pneumonia, skin, soft tissue). However, not all models
were validated, and even when the models were validated, the
validation processes varied.
We reviewed the literature and asked which models for
predicting bacteraemia have been developed; whether the
models were successful in deﬁning a group with a very low
prevalence of bacteraemia and a group with a high prevalence;
and whether they have been validated to such a degree that
their use in clinical practice can be recommended. We also
examined the components of the different models. Finally, we
examined whether the models are being used in routine clinical
practice.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectMethodsWe conducted a comprehensive search in an attempt to
identify studies offering a model to predict bacteraemia. We
searched the PubMed database (inception to September 2014),
combining the terms (predict OR predicting OR prediction)
AND (bacteraemia OR blood stream infection). The bibliog-
raphies of all included studies and pertinent reviews were
scanned for additional references.
We included studies of adult populations where the model
underwent internal or external validation. We extracted data
on baseline study characteristics, whether the original study
was prospective or retrospective, baseline study’s population
characteristics, which parameters were included in the model,
whether the model underwent validation, and if so, which kind,
and the probability of bacteraemia in the high- and low-risk
group. We examined the cutoffs used in the studies against
an arbitrarily chosen deﬁnition of high- or low-risk groups for
bacteraemia: we deﬁned high risk as >30% and low risk as <3%.
We chose a low-risk cutoff that would be lower than the rates
of contamination of blood cultures (which is approximately 3%
to 5%) and a high-risk cutoff based on previous studies [14].
We addressed three types of validation: validation that is done
in a single data set, with techniques such as jackkniﬁng or boot-
strapping, validation done in a second group of patients different
from the original cohort but at the same centre and validation at a
different centre. We deﬁned internal validation as testing of the
model on a group of patients, different than the derivation group,
either from the same cohort or from a different cohort at the
same centre. External validation was deﬁned as testing of the
model in a different group than the derivation group, in a different
centre and at a different time. We searched for interventional
studies that used the models to change the practice of obtaining
blood cultures.We alsowrote to the authors of validatedmodels
and asked whether, to their knowledge, their models are being
used in routine clinical practice.ResultsSearch results
We identiﬁed 710 records on electronic database searches and
retrieved 36 publications for full-text inspection, of which 21
were excluded because they did not have any form of validation.
Description of included studies
Fifteen publications [2,8,14–26], conducted from 1990 through
2014 and including 59 276 patients, were included in the review
(Table 1). All were published in journals; two were in Spanishious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 295–301
TABLE 1. Model characteristics
Study ID Study population
Prospective
study
Parameters included in model
Sepsis signs and symptoms Source Background
Inﬂammation markers or
laboratory values
Bates 1990 [8] Hospitalized patients in whom
blood cultures were drawn
Yes Temp 38.3°C, chills Acute abdomen at examination Major comorbidities, iv drug abuse,
fatal disease
—
Leibovici 1991 [2] Admitted febrile patients Yes Chills Suspected urinary infection Low premorbid performance status Renal failure, low albumin
Mozes 1993 [16] Hospitalized patients in whom
blood cultures were drawn
Yes Temp 39°C Current immunosuppressive therapy,
hospitalization in ICU
Serum alkaline phosphatase >100 IU
Bates 1997 [15] Emergency, ward, and ICU
patients with sepsis
(deﬁned by authors)
Yes Altered mental status, focal
abdominal signs within 24
hours of sepsis onset
Suspected or documented focal
infection at onset
Hickman catheter, absence of antibiotics
at onset, liver disease
—
Metersky 2004 [17] CAP admitted No SBP <90 mm Hg, temp <35°C
or 40°C, pulse 125 bpm
— Liver disease, prior antibiotic therapy BUN 30 mg/dL, Na 130 mmol/L,
WBC <5000/mm3 or >20 000/mm3
Lizarralde 2004 [18] Hospitalized patients in whom
blood cultures were drawn
within 48 hours
Yes Temp >38.3°C Urinary focus — Band forms, ESR 70 mm, Plt <200,000
/μL, Glu 140 mg/dL, urea
50 mg/dL, CRP 12 mg/dL,
albumin <3 g/dL
Paul 2006 [14] Hospitalized patients in whom
blood cultures were drawn
Yes Bayesian prediction model (causal
probabilistic network) using the
site of infection, sepsis signs and
symptoms and inﬂammation
markers
— — —
Shapiro 2008 [19] ED or 3 hours from admission
in whom blood cultures were
drawn
Yes Temp >39.5°C, temp 38.3–39.4°C,
chills, vomiting, SBP <90 mm Hg
Indwelling vascular catheter,
clinical suspicion of endocarditis
Age >65 years Neutrophils >80%, WBC >18 000/mm3,
bands >5%, Plt <150 000/μL,
creatinine >2mg/dl
Falguera 2009 [20] CAP admitted No Tachycardia tachypnea, systolic
hypotension
Pleuritic pain Liver disease, absence of prior
antibiotic treatment
—
Lipsky 2010 [21] Hospitalized patients with SSSI,
with blood culture obtained
within 48 hours of hospitalization
No RR <10 or >29 bpm, pulse <49
or >125 bpm, temp <35.6
or 38°C
Device or prosthesis infection Healthcare-associated infection,
male sex, coronary artery
disease, age
WBC 11 × 109 cells/L, white
blood cell band 7%,
albumin 3 g/dL
Müller 2010 [22] CAP admitted Yes — — — PCT
Tudela 2010 [23] Patients in ED whom blood cultures
were drawn
Yes — — Charlson index 2 PCT >0.4 ng/mL
Kim 2011 [24] Women with pyelonephritis at ED
(fever, pyuria, ﬂank tenderness)
No Vomiting, pulse >110 bpm — Age 65 years Segmented neutrophils >90%,
urine WBCs 50/HPF
Jin 2013 [25] Hospitalized patients in whom
blood cultures were drawn
Yes Hyperthermia, hypothermia,
tachycardia, tachypnea, low SBP
Central venous catheter Sex, age, steroid therapy, antibiotic
therapy
Leukocytosis, leukopenia,
elevated CRP, low Plt,
elevated PT, elevated
creatinine, low albumin,
elevated alkaline phosphatase
Lee 2014 [26] CAP admitted Yes SBP <90 mm Hg, HR >125 bpm,
Temp <35°C or >40°C
— — WBC <4000 or >12 000 cpm,
Plt <130 000 cpm, albumin
<3.3 g/dL, CRP >17 mg/dL
bpm, beats per minute; BUN, blood urea nitrogen; CAP, community-acquired pneumonia; cpm, cells per microliter; CRP, C-reactive protein; ED, emergency department; ESR, erythrocyte sedimentation rate; Glu, glucose; HPF, high-power
ﬁeld; ICU, intensive care unit; iv, intravenous; Na, natrium; PCT, pro calcitonin; Plt, platelets; PT, prothrombin time; RR, respiratory rate; SBP, systolic blood pressure; SSSI, skin and soft tissue infection; Temp, temperature; WBC, white
blood cells.
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298 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMI[18,23] and the rest were in English. Study populations were
heterogeneous, mainly hospitalized patients in which blood
cultures were drawn for any reason (ﬁve studies), hospitalized
with community-acquired pneumonia (four studies) and pa-
tients in the ED for whom blood cultures were drawn (two
studies). Eleven studies were prospective and four retrospec-
tive. All included studies used criteria to deﬁne cultured or-
ganisms as contaminants. Generally, this was deﬁned as an
organism commonly considered a contaminant, grown only in
one culture bottle and in the absence of other evidence of
infection. Contaminants were counted as negative culture re-
sults in all studies. The parameters included in the different
models were signs and symptoms of sepsis, source of sepsis,
background and medical history and biomarkers of inﬂamma-
tion. There were no studies that included the same parameters,
and parameters were greatly different among studies.
Two studies used a Bayesian prediction model (causal
probabilistic network). The rest used a logistic model derived
by multivariable analysis. Ten studies underwent internal vali-
dation where the validation group was from the same site as the
derivation group. The model performed well in all of them. Five
studies performed validation in different populations at a single
site. Seven models were validated externally in a different
hospital, using a new independent database. In two of these, the
model performed poorly.
Validation properties and performance of models in
included studies
To deﬁne risk groups of bacteraemia, patients were classiﬁed into
three to six risk groups in different studies, with variable deﬁni-
tions. This resulted many times in a small number of patients in
the groups of interest: the low- and high-risk groups for bac-
teraemia. Thus, sometimes the probability for true bacteraemia
seemed impressive (very low in the low-risk group or very high in
the high-risk group) but in actuality was less so because the de-
nominator was very small (including only a few patients), and thus
of dubious signiﬁcance for clinical practice (Table 2).
Only three studies met our predeﬁned cutoff criteria for
both high and low risk of bacteraemia, and they found a high-
risk group for bacteraemia of >30% and a low-risk group of
<3% [2,14,26]. One of these performed poorly on external
validation [2], but the two other performed well. Seven other
studies deﬁned a low-risk group of patients with <3% of bac-
teraemia but a high-risk group with a lower percentage than
deﬁned, and ﬁve showed only a high-risk group of >30% but
were not successful in deﬁning a low-risk group. Ten models
published an area under the ROC curve value for the model.
Values were heterogeneous between models, between 0.6 and
0.83, but were not different in derivation versus validation
groups in each study (Table 2).Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectUse of models in clinical practice
Seven of 15 authors replied our query of whether their models
are being used in routine clinical practice, all of them declaring
that the model was not implemented. We found one study that
measured the impact of using the model in practice and
compared the accuracy of the attending physician in diagnosing
bacteraemia (2). This study concluded that use of the model
could have improved the diagnosis accuracy in 5% of the pa-
tients in the low-risk group and 18% in the high-risk group.DiscussionWe found only 15 studies offering a model for prediction of
bacteraemia that underwent validation, evenly divided between
internal and external validation. The models used differing
clinical and laboratory predictors. At least part of the reason
for this is that the models studied different patient populations,
thus resulting in different prediction models, but there are also
variations in practice among settings that could have had an
impact. Ten studies showed a percentage of bacteraemia lower
than 3% in the low-risk group, but in some of these studies, the
model stratiﬁed patients into more than three groups (up to
six), resulting in a small percentage of patients in the low-risk
group.
None of the validated models was used in routine clinical
practice after validation, although they may have been helpful to
clinicians in considering whether or not to perform cultures.
Reasons for this might be that the models were too diagnosis
speciﬁc or cumbersome, or they may have relied on a series of
variables that were not available early enough.
Coburn et al. [27] performed a systematic review in order to
deﬁne clinical and laboratory ﬁndings informative for the deci-
sion to obtain blood cultures in suspected bacteraemia. Running
a search strategy very similar to ours, they found that systemic
inﬂammatory response syndrome and a multivariable decision
rule with major criteria (suspicion of endocarditis, temperature
>39.4°C, indwelling catheter) and minor criteria (temperature
38.3°C to 39.3°C, age >65 years, chills, vomiting, systolic blood
pressure <90 mm Hg, white blood cell count >18 000/μL,
creatinine >2 mg/dL), were sensitive but not speciﬁc predictors
of bacteraemia (negative likelihood ratio 0.09, 95% conﬁdence
interval 0.03–0.26; and negative likelihood ratio 0.08, 95%
conﬁdence interval 0.04–0.17, respectively). They concluded
that systemic inﬂammatory response syndrome and this deci-
sion rule may be helpful in identifying immunocompetent pa-
tients who do not need blood cultures. However, their review
took into account all models, regardless of whether or not they
were validated, and they did not include models from the year
2012 and later.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 295–301
TABLE 2. Validation properties and probabilities of bacteraemia
Study
Internal validation
External validation
Area under the ROC curve for mode
Probability of true bacteraemia
low-risk group
Probability of true bacteraemia
high-risk group
One
database
Two different
databases Deviation Validation Deviation Validation Derivation Validation
Bates 1990 [8]
(d = 1007, v = 509)
Yes Performed poorly 4/303 (1%) 3/155 (2%) 41/264 (16%)
Leibovici 1991 [2]
(d = 244, v = 257)
Yes Performed poorly 7/146 (5%) 1/131 (1%) 5/6 (83%) 11/7 (65%)
Mozes 1993 [16]
(d = 474, v = 438)
Yes Not done 12/240 (5.1%) 9/194 (4.6%) 23/62 (38%) 8/65 (12.1%) (p < 0.01)
Bates 1997 [15]
(d = 881, v = 461)
Yes Not done 0.60 ± 0.04 0.62 ± 0.03 32/220 (14.5%) 19/126 (15%) 62/102 (60.6%) 26/40 (64.4%)
Metersky 2004 [17]
(d = 13 043, v = 12 771)
Yes Not done 0.68 (95%
CI 0.66–0.70)
0.68 (95% CI 0.66–0.70) 53/2243 (2%) 61/2245 (3%) 322/2297 (14%) 376/2417 (16%)
Lizarralde 2004 [18]
(d = 298, v = 150)
Yes Not done 0.81 (95%
CI 0.76–0.86)
0.77 (95% CI 0.69–0.85) 2/84 (2.4%) 2/49 (4.1%) 26/40 (65%) 12/15 (80%)
Paul 2006 [14]
(d = 790, v = 1724)
Yes Performed well—3 sites 0.68 95%
CI 0.63–0.73;
p < 0.001)
0.70 (95% CI 0.67–0.73;
p < 0.001)
3/123 (2.4%) 4/300 (1.3%) 55/184 (29.9%) 80/184 (28.1%)
Shapiro 2008 [19]
(d = 2466, internal
v = 1264, external v = 1526)
Yes Performed well— independent
hospital emergency department
0.8 I = 0.75, E = 0.83 4/659 (0.6%) I = 3/338 (0.9%) 106/414 (26%) I = 33/214 (15%)
Falguera 2009 [20]
(d = 1386, internal
v = 900, external v = 1127)
Yes Performed well— independent
multicentre cohort
4/133 (3%) I = 2/66 (3%),
E = 4/133 (3%)
16/42 (38%) I = 20/31 (63%),
E = 10/34 (29%)
Lipsky 2010 [21]
(d = 755, v = 266)
Yes Not done 3% 4% 46% 44%
Müller 2010 [22]
(d = 463, v = 462)
Yes Not done 0.83 (95%
CI 0.78–0.89)
0.79 (95% CI 0.72–0.88) 1/117 (0.9%) 0% 61/364 (16.8%) 11%
Tudela 2010 [23]
(d = 206, v = 206)
Yes Not done 0.8 0.74 0% 2.9% 35% 27.2%
Kim 2011 [24]
(d = 494, internal v = 241,
external v = 169)
Yes Performed well— independent
academic hospital emergency
department
0.792 I = 0.707, E = 0.792 9/208 (4.3%) I = 9/106 (8.5%),
E = 3/53 (5.7%)
60/118 (50.9%) I = 21/50 (42%),
E = 31/55 (56.4%)
Jin 2013 [25]
(d = 11 061, v = 2341)
Yes Not done 0.70 ± 0.007 0.70 ± 0.018 68/3594 (1.9%) 1/260 (0.4%) 97/486 (20%) 25/136 (18.4%)
Lee 2014 [26]
(d = 1475, v = 947)
Yes Performed well—cohort from
an independent hospital
0.75 31/1144 (2.7%) I = 20/746 (2.6%),
E = 25/1070 (2.3%)
11/37 (29.7%) I = 5/16 (31.2%),
E = 10/44 (22.7%)
d, deviation cohort number; CI, conﬁdence interval; E, external; I, internal; ROC, receiver operating characteristic; v, validation cohort number.
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300 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMITwo of the predictive models we identiﬁed performed
poorly in external validations [2,8]. Mylotte et al. [28] tested the
model of Bates et al. [8] and found an ROC area of only 0.64,
compared with 0.72 in the original model. Yehezkelli et al. [29]
tested the 2 models developed by Bates [8] and Leibovici [2]
and also found signiﬁcant deterioration in performance.
Mozes et al. [16] suggested several factors contributing to these
limitations of previous models: varying inclusion criteria, dif-
ferences in deﬁnitions of predictors, overrepresentation of
groups, varying practice styles and variation in measurement
and interpretation of data. An example of differences between
sites is that intravenous drug abuse was a strong predictor of
bacteraemia in the Bates model, but there were few intrave-
nous drug abusers where it was validated.
We found two attempts to predict bacteraemia using a
computerized decision-support system. Paul et al. [14] con-
structed a system based on a causal probabilistic network
(TREAT). The area under the ROC curve for prediction of
bacteraemia was 0.68 in the derivation cohort and 0.70 in the
validation cohort. The prevalence of bacteraemia was 2.4% in
the low-risk group and 29.9% in the high-risk group. The
TREAT system performance was validated in different settings
(internal and external validation). Jin et al. [25] constructed a
Bayesian prediction model. The model underwent only internal
validation and performed well; the area under the ROC curve
for prediction of bacteraemia was 0.7 in the derivation and
validation cohort. The prevalence of bacteraemia was 0.4% in
the low-risk group and 20% in the high-risk group.
Schurink et al. [30] discussed the historical developments,
possibilities and limitations of various computer-based decision-
support models for infectious diseases. They stated that
because clinical experience is limited and clinicians are generally
reluctant to use computerized guidelines if they require addi-
tional data entry, time and effort, prospective evaluation is
needed to provide evidence on which implementation and
wide-scale use of decision-support systems can be based.
However, things are changing as electronic health records are
becoming the norm, and it may be possible to use clinical data
to predict who is infected and at risk of sepsis or bacteraemia
[31]. In one recent study, Schmidt et al. [32] evaluated the
impact of evaluating changes in vital sign parameters in hospi-
talized patients, and when a deterioration was found suggesting
decompensation, this was communicated to providers. This
resulted in a mortality reduction in two geographically sepa-
rated hospitals. A host of sensors are becoming available, and
when linked to communication tools and used with analytics,
these approaches have substantial potential for improving
outcomes, including in patients with suspected infection [33].
An important general frontier in informatics, as the use of
electronic health records rises, is how to get clinicians to useClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectprediction rules like these, and how to manage issues such as
missing data in the rules in real time.
Conclusions
Although many models for predicting bacteraemia in adults
have been developed, very few have been prospectively vali-
dated and performed well. Moreover, even these are not yet
used in clinical practice. Reluctance to use these models is
probably rooted in the additional work required to enter data
and use the models; in the availability of the models’ compo-
nents in real time for septic patients; and in the additional in-
formation that might be gained from blood cultures even in
patients with an a priori low probability of bacteraemia.
Future research
In an ideal world, the way to move forward would be to use
the existing, recent, prospective databases in order to reach an
acceptable model (or adopt from present ones). A threshold
for the low-risk group (deﬁned by us arbitrarily as <3%) should
be deﬁned in a formal cost-effectiveness analysis. The model
should be tested in a clinical trial to examine whether it is
helpful and safe in clinical use. Clinical trials preferably should
be multicentred in order to secure utility and safety in diverse
clinical settings. It may be possible to develop such models
soon and implement them in routine care, given the advent of
electronic health records and the growing availability of elec-
tronic clinical data, especially vital signs and laboratory
parameters.Transparency declarationThis review was conducted as part of our routine work. LL is
on the scientiﬁc board of TREAT Systems. DWB serves as a
consultant to and has received research support from Ear-
lySense. The other authors report no conﬂicts of interest
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